Antares Pharma — Investor Presentation (January 2019)
24 slides from Antares Pharma's investor presentation, Jan 7, 2019
Slide 1: January 2019 Investor Presentation
NASDAQ: ATRS January 2019 Investor Presentation EX 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ mate
Slide 3: Antares Pharma: A Growing Specialty Pharmaceutical Company
Antares Pharma A Growing Specialty Pharmaceutical Company with 2017 Revenue of $54.5 Million – 2018 year-to-date revenue through September 30 of $44.7 Million ATRS previously announced full year 2018 revenue guidance to be in the range of $60-$65 million Company now projects full year revenue guidan
Slide 4: Antares Pharma – 2018 Significant Achievements
Antares Pharma – 2018 Significant Achievements February approval of AMAG’s Makena® auto injector product utilizing QuickShot® device August approval of Teva’s therapeutically equivalent generic EpiPen® August Alliance Business transaction signed – Pfizer Rescue Pen XYOSTED™ NDA approved September XY
Slide 5: A New Choice in the Management of Testosterone Deficiency
A NEW CHOICE in the Management of TESTOSTERONE DEFICIENCY The first and only weekly auto-injector for TRT
Slide 6: XYOSTED Product Features
PRODUCT FEATURES Easy to use and store at room temperature Fine (27-gauge) needle allows for rapid subcutaneous delivery of sesame oil solution (~10 seconds) Locking needle guard hides needle before, during, and after administration and reduces risk of needle stick injuries TE, testosterone enanthat
Slide 7: Ctrough Stable For Weeks
Ctrough Stable For 52 Weeks Mean Ctrough (ng/dL) over 52 week “003” study 6 12 18 26 38 52 Week 1, pre-dose QST-13-003 treatment regimen demonstrated a mean steady state concentration of testosterone of 553.3 ± 127.3 ng/dL at 12 weeks Orange lines represent the defined range of 300 – 1100 ng/dL . .
Slide 8: XYOSTED Commercial Launch
XYOSTED™ Commercial Launch Recruitment of ~60 sales representatives Finalize Payer Access Strategy and continue contracting discussions with large plans and PBM’s Execution on all Marketing Assets and Activities Distribution Strategy and Trade Negotiations WAC - $475 per month Marketing Managed Mark
Slide 9: Unique Messaging: 98.5% of P3 XYOSTED Patients in Physiologic Range
Unique Messaging: 98.5% of P3 XYOSTED™ patients achieved levels in the physiologic range With XYOSTED™, consistent steady state, physiologic levels are achieved in 6 weeks and then maintained over a year in the P3 study In a P3 clinical study, 99.4% of observed injections were virtually pain-free Co
Slide 10: Testosterone Replacement Market: Jan 2015 – Nov 2018
Testosterone Replacement Market: Jan 2015 – Nov 2018 Retail Prescriptions 2016 2015 2018 Data Source - IQVIA 10
Slide 11: Antares Partnered Commercial Products
NASDAQ: ATRS Antares Partnered Commercial Products
Slide 12: Teva's Epinephrine Injection USP Approved Utilizing VIBEX Device
Teva’s Epinephrine Injection USP Approved Utilizing ATRS VIBEX® Device Teva’s generic EpiPen® was approved by FDA on August 16, 2018 Therapeutically equivalent and fully substitutable at the pharmacy Antares received a $2 million milestone payment from Teva upon approval Pre-launch devices have been
Slide 13: Makena Utilizing ATRS QuickShot Device
Makena® hydroxyprogesterone caproate injection Utilizing ATRS QuickShot® Device Subcutaneous injection Intramuscular injection Efficient Discreet Administration friendly ü ü ü Makena® - Used to Reduce the Risk of Preterm Birth in Certain At-Risk Women Approved February ‘18 - YTD through 9/30/18 tota
Slide 14: Antares Proprietary Commercial Products
NASDAQ: ATRS Antares Proprietary Commercial Products
Slide 15: ATRS FDA Approved Commercial Products
ATRS FDA Approved Commercial Products OTREXUP® (methotrexate) injection Sumatriptan Injection USP (VIBEX® Device) (VIBEX® Device)
Slide 16: Alliance Business Pipeline
NASDAQ: ATRS Alliance Business Pipeline
Slide 17: Generic Forteo (teriparatide)
Generic Forteo® (teriparatide) 17 Teva ANDA accepted by FDA and is currently under active review Teva and Eli Lilly settled their Paragraph IV litigation in the U.S. with terms undisclosed. Lilly has stated they do not expect any generic competition until the second half of 2019 Teva has successfull
Slide 18: ATRS/Pfizer Strategic Collaboration for Rescue Pen
ATRS/Pfizer Strategic Collaboration for Rescue Pen Antares and Pfizer are developing a combination drug device Rescue Pen The Rescue Pen will utilize the Antares QuickShot® device and an undisclosed Pfizer drug Pfizer will pay for the development of the product and assume responsibility for FDA appr
Slide 19: Generic Byetta (exenatide)
Generic Byetta® (exenatide) Teva is working through the FDA regulatory approval process using the ANDA pathway ATRS believes Teva has first to file status and therefore 180 days of marketing exclusivity pending FDA approval and launch Total gross U.S. sales of Byetta® in 2017 were approximately $259
Slide 20: ATRS Year-To-Date Financial Schedules
NASDAQ: ATRS ATRS Year-To-Date Financial Schedules
Slide 21: Third Quarter and Year-to-Date 2018 Financial Results
Third Quarter and Year-to-Date 2018 Financial Results Three Months Ended Sept 30 Increase Nine Months Ended Sept 30 Increase 2018 2017 (Decrease) 2018 2017 (Decrease) Total Revenue $ 17,868 $ 15,052 19% $ 44,733 $ 40,476 11% Cost of Revenue 7,289 8,523 (14%) 21,435 20,359 5% Gross Profit 10,579 6,52
Slide 22: ATRS Projected Five Year Revenue Growth
ATRS Projected Five Year Revenue Growth Projected CAGR – 30.4% Guidance Guidance +14.2% vs. ‘15 +72.5% vs. ‘14 +15% - 19% vs. ‘17 +46% - 68% vs. ’18* * Percent increase based on 2018 guidance
Slide 23: ATRS – Investment Considerations
ATRS – Investment Considerations XYOSTED™ launch – Sales Reps deployed mid-December 2018 Teva’s generic EpiPen® launch and new device orders received for restocking Potential continued growth of AMAG’s Makena® SC auto injector product Potential U.S. FDA approval and global launch of generic Forteo®
Slide 24: January 2019
NASDAQ: ATRS January 2019 Investor Presentation
Antares Pharma — Investor Presentation (January 2019) on 6ix